Bookmark and Share

Rectification of the Register – A Singapore Perspective

Issued: March 29 2018

In Novartis (Singapore) Pte Ltd v. Bristol-Myers Squibb Pharma Co, the Singapore High Court addressed key procedural issues associated with corrections to patent forms and priority data, as well as corrections to the Singapore Patents Register. Gladys Mirandah and Suhaimi Bin Lazim explain.

 

Related Articles

  • Commercial Disparagement: View of the In...
    Indian filmmakers have been taken to court numerous times by trademark holders alleging commercial disparagement and other similar clai...
  • The Amazing Enforce-Men
    In comics, Spider-Man fights off villains all by himself, but in reality, IP enforcement is not done by one person or unit – it include...
  • Follow-on Biologics: Is Your Patent Port...
    Recent health insurance reform legislation made headlines throughout the United States for its sweeping reforms to how Americans will r...
  • Taking Your Trademark to the World
    The increasing acceptance of e-commerce means that even small businesses can have global reach. Going global means that a business must...
  • The Patent War
    As the legal confrontation between technology titans Apple and Samsung turns white hot, Anna Zhang speaks to lawyers and top industry a...
  • Is There Copyright in This Headline? Not...
    Australia’s Federal Court has ruled that there is no copyright in newspaper headlines. John Fairbairn dissects the ruling and what it w...
 

Law Firms